DK2247592T3 - Pyrrolopyrazinkinaseinhibitors - Google Patents
PyrrolopyrazinkinaseinhibitorsInfo
- Publication number
- DK2247592T3 DK2247592T3 DK09713736.8T DK09713736T DK2247592T3 DK 2247592 T3 DK2247592 T3 DK 2247592T3 DK 09713736 T DK09713736 T DK 09713736T DK 2247592 T3 DK2247592 T3 DK 2247592T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitors
- pyrrolopyrazine
- pyrrolopyrazine kinase
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3103508P | 2008-02-25 | 2008-02-25 | |
| US20572409P | 2009-01-22 | 2009-01-22 | |
| PCT/EP2009/051757 WO2009106442A1 (en) | 2008-02-25 | 2009-02-16 | Pyrrolopyrazine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2247592T3 true DK2247592T3 (da) | 2011-09-26 |
Family
ID=40514094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09713736.8T DK2247592T3 (da) | 2008-02-25 | 2009-02-16 | Pyrrolopyrazinkinaseinhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7939531B2 (da) |
| EP (1) | EP2247592B1 (da) |
| JP (1) | JP5368485B2 (da) |
| KR (1) | KR101261514B1 (da) |
| CN (1) | CN101939324B (da) |
| AR (1) | AR070468A1 (da) |
| AT (1) | ATE522535T1 (da) |
| AU (1) | AU2009218607B2 (da) |
| BR (1) | BRPI0908494A2 (da) |
| CA (1) | CA2713710A1 (da) |
| CL (1) | CL2009000406A1 (da) |
| DK (1) | DK2247592T3 (da) |
| IL (1) | IL206358A0 (da) |
| MX (1) | MX2010008198A (da) |
| PE (1) | PE20091493A1 (da) |
| PL (1) | PL2247592T3 (da) |
| PT (1) | PT2247592E (da) |
| RU (1) | RU2503676C2 (da) |
| TW (1) | TWI380987B (da) |
| WO (1) | WO2009106442A1 (da) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009106445A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| WO2009106443A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| CA2713324A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| WO2009106444A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
| US8426411B2 (en) | 2008-06-10 | 2013-04-23 | Abbott Laboratories | Tricyclic compounds |
| JP5748659B2 (ja) | 2008-06-10 | 2015-07-15 | アッヴィ・インコーポレイテッド | 新規な三環式化合物 |
| MX2011004953A (es) | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
| AU2009327357C1 (en) | 2008-12-19 | 2017-02-02 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of ATR kinase |
| SG10201405826RA (en) | 2009-06-17 | 2014-12-30 | Vertex Pharma | Inhibitors of influenza viruses replication |
| TW201120041A (en) * | 2009-09-10 | 2011-06-16 | Hoffmann La Roche | Inhibitors of JAK |
| CA2781010A1 (en) | 2009-12-01 | 2011-06-09 | Abbott Laboratories | Novel tricyclic compounds |
| EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
| AU2011210765A1 (en) | 2010-01-28 | 2012-09-13 | President And Fellows Of Harvard College | Compositions and methods for enhancing proteasome activity |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| US8481541B2 (en) * | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
| CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
| EP2569313A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピラジン |
| BR112012029437A2 (pt) * | 2010-05-20 | 2017-03-07 | F Hoffmann - La Roche Ag | derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk |
| TWI496785B (zh) * | 2010-05-20 | 2015-08-21 | Hoffmann La Roche | 吡咯并吡激酶抑制劑 |
| US8846909B2 (en) * | 2010-05-24 | 2014-09-30 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| EP2585468A1 (en) | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| DE102011009961A1 (de) * | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
| WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| US9556166B2 (en) | 2011-05-12 | 2017-01-31 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
| JP2014520161A (ja) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
| US9096602B2 (en) * | 2011-06-22 | 2015-08-04 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-B]pyrazines as ATR kinase inhibitors |
| WO2013006634A2 (en) * | 2011-07-05 | 2013-01-10 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| CN104024258B (zh) * | 2011-09-01 | 2017-02-15 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
| EP2763990B1 (en) | 2011-09-01 | 2017-02-22 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049722A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2751097A2 (en) | 2011-09-30 | 2014-07-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of atr kinase |
| KR102056586B1 (ko) | 2011-09-30 | 2019-12-18 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 억제제를 이용한 췌장암 및 비소세포 폐암의 치료 |
| EP2773645A1 (en) | 2011-11-01 | 2014-09-10 | F.Hoffmann-La Roche Ag | Imidazopyridazine compounds |
| US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CN104159891B (zh) | 2012-01-10 | 2016-09-07 | 霍夫曼-拉罗奇有限公司 | 哒嗪酰胺化合物和它们作为syk 抑制剂的用途 |
| NZ726671A (en) | 2012-04-05 | 2018-04-27 | Vertex Pharma | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| BR112015002262A2 (pt) * | 2012-08-21 | 2019-12-10 | Hoffmann La Roche | compostos, métodos para os tratamentos de uma condição inflamatória, artrite reumatóide, asma e distúrbio imunológico; composição farmacêutica, utilização do composto e invenção |
| HUE044146T2 (hu) | 2012-09-10 | 2019-09-30 | Principia Biopharma Inc | Pirazolopirimidin vegyületek mint kináz inhibitorok |
| EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
| WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2014081732A1 (en) | 2012-11-20 | 2014-05-30 | Principia Biopharma Inc. | Azaindole derivatives as jak3 inhibitors |
| WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
| ES2669423T3 (es) | 2012-12-07 | 2018-05-25 | Vertex Pharmaceuticals Incorporated | 2-Amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-il)piperazin-1-carbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-carboxamida como inhibidor de ATR quinasa |
| US9849135B2 (en) | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| US9403780B2 (en) | 2013-05-14 | 2016-08-02 | 3M Innovative Properties Company | Pyridine- or pyrazine-containing compounds |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| LT3068782T (lt) | 2013-11-13 | 2018-09-10 | Vertex Pharmaceuticals Incorporated | Gripo virusų replikacijos inhibitorių paruošimo būdai |
| EP3074025A1 (en) | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| CN103665803B (zh) * | 2013-12-05 | 2015-07-01 | 湖南大学 | 一种基于金属环钯化合物的结晶聚乳酸及其制备方法和金属环钯化合物的应用 |
| MX370390B (es) | 2013-12-06 | 2019-12-11 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. |
| PT3107544T (pt) | 2014-02-21 | 2021-01-05 | Principia Biopharma Inc | Sais e forma sólida de um inibidor de btk |
| ES2777608T3 (es) | 2014-06-05 | 2020-08-05 | Vertex Pharma | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo |
| NZ727399A (en) | 2014-06-17 | 2022-07-29 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| AU2015283850B2 (en) | 2014-07-03 | 2020-06-04 | Board Of Regents, University Of Texas System | GLS1 inhibitors for treating disease |
| WO2016004413A2 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
| PL3233103T3 (pl) | 2014-12-18 | 2021-04-19 | Principia Biopharma Inc. | Leczenie pęcherzycy |
| US10703756B2 (en) | 2015-05-01 | 2020-07-07 | Pfizer Inc. | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| WO2016210165A1 (en) | 2015-06-24 | 2016-12-29 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN107921044B (zh) | 2015-06-30 | 2022-01-21 | 德州大学系统董事会 | 用于治疗疾病的gls1抑制剂 |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG11201802990RA (en) | 2015-10-16 | 2018-05-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| MX2018007143A (es) | 2015-12-22 | 2018-11-29 | Univ Texas | Formas de sales y polimorfos de (r)-1-(4-(6-(2-(4-(3,3-difluorocic lobutoxi)-6-metilpiridin-2-il)acetamido)piridazin-3-il)-2-fluorob util)-n-metil-1h-1,2,3-triazol-4-carboxamida. |
| CA3028169A1 (en) | 2016-06-29 | 2018-01-04 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
| JP7361687B2 (ja) | 2017-10-18 | 2023-10-16 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | グルタミナーゼ阻害薬療法 |
| CN112105359B (zh) * | 2017-12-04 | 2023-12-01 | 豪夫迈·罗氏有限公司 | 作为cccDNA抑制剂用于治疗乙型肝炎病毒(HBV)感染的吡咯并[2,3-b]吡嗪化合物 |
| MX2020007031A (es) * | 2018-01-05 | 2020-12-03 | Ac Immune Sa | Derivados de 1,3,4,5-tetrahidro -2 h-pirido [4,3-b] indol para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau tales como la enfermedad de alzheimer. |
| MX2022000140A (es) * | 2019-07-03 | 2022-04-27 | Borah Inc | Compuestos quimicos. |
| BR112022011838A2 (pt) | 2019-12-20 | 2022-08-30 | Pfizer | Derivados de benzimidazol |
| WO2023025109A1 (zh) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1087970B1 (en) * | 1998-06-19 | 2004-04-28 | Pfizer Products Inc. | PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| EP1263759B1 (en) * | 1999-12-24 | 2010-09-08 | Aventis Pharma Limited | Azaindoles |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| US7534800B2 (en) * | 2002-03-28 | 2009-05-19 | Eisai R & D Development Co., Ltd. | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders |
| WO2005062795A2 (en) | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Compounds and methods for development of ret modulators |
| US20070066641A1 (en) * | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| AU2005269387A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
| RU2394825C2 (ru) * | 2004-11-22 | 2010-07-20 | Вертекс Фармасьютикалз Инкорпорейтед | Пирролопиразины, пригодные в качестве ингибиторов киназы аврора а |
| US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
| WO2007015866A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
| CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
| WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| PE20121126A1 (es) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
-
2009
- 2009-02-16 BR BRPI0908494-0A patent/BRPI0908494A2/pt not_active IP Right Cessation
- 2009-02-16 EP EP09713736A patent/EP2247592B1/en not_active Not-in-force
- 2009-02-16 PT PT09713736T patent/PT2247592E/pt unknown
- 2009-02-16 DK DK09713736.8T patent/DK2247592T3/da active
- 2009-02-16 KR KR1020107018678A patent/KR101261514B1/ko not_active IP Right Cessation
- 2009-02-16 PL PL09713736T patent/PL2247592T3/pl unknown
- 2009-02-16 AU AU2009218607A patent/AU2009218607B2/en not_active Ceased
- 2009-02-16 AT AT09713736T patent/ATE522535T1/de active
- 2009-02-16 MX MX2010008198A patent/MX2010008198A/es active IP Right Grant
- 2009-02-16 JP JP2010548069A patent/JP5368485B2/ja not_active Expired - Fee Related
- 2009-02-16 RU RU2010139566/04A patent/RU2503676C2/ru not_active IP Right Cessation
- 2009-02-16 CN CN200980104705.5A patent/CN101939324B/zh not_active Expired - Fee Related
- 2009-02-16 CA CA2713710A patent/CA2713710A1/en not_active Abandoned
- 2009-02-16 WO PCT/EP2009/051757 patent/WO2009106442A1/en active Application Filing
- 2009-02-20 US US12/378,978 patent/US7939531B2/en not_active Expired - Fee Related
- 2009-02-23 PE PE2009000259A patent/PE20091493A1/es not_active Application Discontinuation
- 2009-02-23 AR ARP090100621A patent/AR070468A1/es unknown
- 2009-02-23 CL CL2009000406A patent/CL2009000406A1/es unknown
- 2009-02-23 TW TW098105681A patent/TWI380987B/zh not_active IP Right Cessation
-
2010
- 2010-06-14 IL IL206358A patent/IL206358A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7939531B2 (en) | 2011-05-10 |
| RU2010139566A (ru) | 2012-04-10 |
| AU2009218607A1 (en) | 2009-09-03 |
| ATE522535T1 (de) | 2011-09-15 |
| CL2009000406A1 (es) | 2010-09-21 |
| US20090215750A1 (en) | 2009-08-27 |
| PE20091493A1 (es) | 2009-09-25 |
| AR070468A1 (es) | 2010-04-07 |
| PT2247592E (pt) | 2011-11-03 |
| CN101939324A (zh) | 2011-01-05 |
| EP2247592A1 (en) | 2010-11-10 |
| MX2010008198A (es) | 2010-08-23 |
| JP5368485B2 (ja) | 2013-12-18 |
| KR101261514B1 (ko) | 2013-05-07 |
| CA2713710A1 (en) | 2009-09-03 |
| IL206358A0 (en) | 2010-12-30 |
| AU2009218607B2 (en) | 2014-02-13 |
| TW200938547A (en) | 2009-09-16 |
| CN101939324B (zh) | 2014-10-15 |
| EP2247592B1 (en) | 2011-08-31 |
| RU2503676C2 (ru) | 2014-01-10 |
| BRPI0908494A2 (pt) | 2015-08-11 |
| KR20100114094A (ko) | 2010-10-22 |
| JP2011513262A (ja) | 2011-04-28 |
| PL2247592T3 (pl) | 2012-01-31 |
| WO2009106442A1 (en) | 2009-09-03 |
| TWI380987B (zh) | 2013-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2020024I1 (el) | Αναστολεiς βητα-λακταμασων | |
| DK2247592T3 (da) | Pyrrolopyrazinkinaseinhibitors | |
| ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
| CY2019009I1 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| CY2019027I2 (el) | Παραγωγα φωσφορου ως αναστολεις κινασης | |
| BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
| BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
| BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| BRPI0922937A2 (pt) | inibidores de pirrolopirazinil uréia quinase | |
| BRPI0922962A2 (pt) | inibidores de p38 map quinase | |
| BRPI0922880A2 (pt) | compostos inibidores de quinase | |
| DK2350047T3 (da) | p38-MAP-KINASEINHIBITORER | |
| BRPI0906838A2 (pt) | Pirimidinas como inibidores de quinase | |
| BRPI0814797A2 (pt) | Inibidores dna-pk | |
| BRPI0912475A2 (pt) | compostos como inibidores de quinase | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0716198A2 (pt) | Pirrolo-isoquinolinas como inibidores de cinase | |
| EP2231152A4 (en) | THIENOPYRANONES AS KINASE INHIBITORS | |
| BRPI0914936A2 (pt) | naftiridininonas como inibidores de aurora quinase | |
| BRPI0912564A2 (pt) | inibidores de jnk | |
| DK2170891T3 (da) | Pyrazolopyrimidinon-kinasehæmmere | |
| LTPA2019004I1 (lt) | Baltymų kinazės slopikliai | |
| ZA201004903B (en) | Pyrrolopyrazine kinase inhibitors | |
| TH105559B (th) | สารยับยั้งไคเนสไพร์โรโลไพราซีน |